| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8703806 | ASTRAZENECA | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
May, 2030
(6 years from now) | |
| US10716753 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US8324266 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
| US8808713 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US9463161 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
May, 2030
(6 years from now) | |
| US9415009 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(6 years from now) | |
| US8815258 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
Mar, 2031
(6 years from now) | |
Bevespi Aerosphere is owned by Astrazeneca.
Bevespi Aerosphere contains Formoterol Fumarate; Glycopyrrolate.
Bevespi Aerosphere has a total of 7 drug patents out of which 0 drug patents have expired.
Bevespi Aerosphere was authorised for market use on 25 April, 2016.
Bevespi Aerosphere is available in aerosol, metered;inhalation dosage forms.
Bevespi Aerosphere can be used as use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd).
The generics of Bevespi Aerosphere are possible to be released after 17 March, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 25, 2019 |
Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED;INHALATION
BEVESPI AEROSPHERE family patents
